resiquimod has been researched along with Bronchial Hyperreactivity in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ahrens, B; Hamelmann, E; Joachim, RA; Kallinich, T; Quarcoo, D; Stock, P; Weixler, S | 1 |
Alber, G; Bauer, S; Garn, H; Renz, H; Sel, S; Wegmann, M | 1 |
2 other study(ies) available for resiquimod and Bronchial Hyperreactivity
Article | Year |
---|---|
Resiquimod, a new immune response modifier from the family of imidazoquinolinamines, inhibits allergen-induced Th2 responses, airway inflammation and airway hyper-reactivity in mice.
Topics: Allergens; Animals; Asthma; Bronchi; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Female; Imidazoles; Immunologic Factors; Interferon-gamma; Interleukin-12; Interleukin-4; Interleukin-5; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Ovalbumin; Th2 Cells | 2004 |
Immunomodulatory effects of viral TLR ligands on experimental asthma depend on the additive effects of IL-12 and IL-10.
Topics: Animals; Antibodies; Antiviral Agents; Asthma; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Cytokines; Female; Imidazoles; Immunoglobulin E; Immunoglobulin G; Immunosuppression Therapy; Interleukin-10; Interleukin-12; Interleukin-12 Subunit p35; Ligands; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Mutant Strains; Ovalbumin; Poly I-C; Toll-Like Receptor 3; Toll-Like Receptor 7 | 2007 |